297 related articles for article (PubMed ID: 21081840)
1. Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma.
Nguyen T; Kuo C; Nicholl MB; Sim MS; Turner RR; Morton DL; Hoon DS
Epigenetics; 2011 Mar; 6(3):388-94. PubMed ID: 21081840
[TBL] [Abstract][Full Text] [Related]
2. CpG island methylator phenotype predicts progression of malignant melanoma.
Tanemura A; Terando AM; Sim MS; van Hoesel AQ; de Maat MF; Morton DL; Hoon DS
Clin Cancer Res; 2009 Mar; 15(5):1801-7. PubMed ID: 19223509
[TBL] [Abstract][Full Text] [Related]
3. Loss of post-transcriptional regulation of DNMT3b by microRNAs: a possible molecular mechanism for the hypermethylation defect observed in a subset of breast cancer cell lines.
Sandhu R; Rivenbark AG; Coleman WB
Int J Oncol; 2012 Aug; 41(2):721-32. PubMed ID: 22664488
[TBL] [Abstract][Full Text] [Related]
4. miR-29c-3p regulates DNMT3B and LATS1 methylation to inhibit tumor progression in hepatocellular carcinoma.
Wu H; Zhang W; Wu Z; Liu Y; Shi Y; Gong J; Shen W; Liu C
Cell Death Dis; 2019 Jan; 10(2):48. PubMed ID: 30718452
[TBL] [Abstract][Full Text] [Related]
5. AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome.
Hoshimoto S; Kuo CT; Chong KK; Takeshima TL; Takei Y; Li MW; Huang SK; Sim MS; Morton DL; Hoon DS
J Invest Dermatol; 2012 Jun; 132(6):1689-97. PubMed ID: 22402438
[TBL] [Abstract][Full Text] [Related]
6. miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway.
Li W; Yi J; Zheng X; Liu S; Fu W; Ren L; Li L; Hoon DSB; Wang J; Du G
Clin Epigenetics; 2018; 10():64. PubMed ID: 29796115
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of microRNA expression drives aberrant DNA hypermethylation in basal-like breast cancer.
Sandhu R; Rivenbark AG; Mackler RM; Livasy CA; Coleman WB
Int J Oncol; 2014 Feb; 44(2):563-72. PubMed ID: 24297604
[TBL] [Abstract][Full Text] [Related]
8. Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma.
Kitago M; Martinez SR; Nakamura T; Sim MS; Hoon DS
Clin Cancer Res; 2009 May; 15(9):2988-94. PubMed ID: 19336521
[TBL] [Abstract][Full Text] [Related]
9. Suppressing microRNA-29c promotes biliary atresia-related fibrosis by targeting DNMT3A and DNMT3B.
Wang JY; Cheng H; Zhang HY; Ye YQ; Feng Q; Chen ZM; Zheng YL; Wu ZG; Wang B; Yao J
Cell Mol Biol Lett; 2019; 24():10. PubMed ID: 30906331
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms underlying aberrant expression of miR-29c in uterine leiomyoma.
Chuang TD; Khorram O
Fertil Steril; 2016 Jan; 105(1):236-45.e1. PubMed ID: 26453978
[TBL] [Abstract][Full Text] [Related]
11. B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma.
Wang J; Chong KK; Nakamura Y; Nguyen L; Huang SK; Kuo C; Zhang W; Yu H; Morton DL; Hoon DS
J Invest Dermatol; 2013 Aug; 133(8):2050-8. PubMed ID: 23474948
[TBL] [Abstract][Full Text] [Related]
12. Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease.
Ben Gacem R; Ben Abdelkrim O; Ziadi S; Ben Dhiab M; Trimeche M
Tumour Biol; 2014 May; 35(5):4047-56. PubMed ID: 24375250
[TBL] [Abstract][Full Text] [Related]
13. Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanoma.
Huynh KT; Takei Y; Kuo C; Scolyer RA; Murali R; Chong K; Takeshima L; Sim MS; Morton DL; Turner RR; Thompson JF; Hoon DS
Br J Dermatol; 2012 Jun; 166(6):1319-26. PubMed ID: 22293026
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-22 targets FMNL2 to inhibit melanoma progression via the regulation of the Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition.
Shi L; Huo JW; Chen SS; Xue JX; Gao WY; Li XY; Song YH; Xu HT; Zhu XW; Chen K
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5332-5342. PubMed ID: 31298385
[TBL] [Abstract][Full Text] [Related]
16. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients.
Hoon DS; Spugnardi M; Kuo C; Huang SK; Morton DL; Taback B
Oncogene; 2004 May; 23(22):4014-22. PubMed ID: 15064737
[TBL] [Abstract][Full Text] [Related]
17. Promoter methylation status of multiple genes in uveal melanoma.
Merhavi E; Cohen Y; Avraham BC; Frenkel S; Chowers I; Pe'er J; Goldenberg-Cohen N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4403-6. PubMed ID: 17898258
[TBL] [Abstract][Full Text] [Related]
18. Molecular Subtype-Specific Expression of MicroRNA-29c in Breast Cancer Is Associated with CpG Dinucleotide Methylation of the Promoter.
Poli E; Zhang J; Nwachukwu C; Zheng Y; Adedokun B; Olopade OI; Han YJ
PLoS One; 2015; 10(11):e0142224. PubMed ID: 26539832
[TBL] [Abstract][Full Text] [Related]
19. Aberrant DNA methylation is associated with aggressive clinicopathological features and poor survival in cutaneous melanoma.
de Unamuno Bustos B; Murria Estal R; Pérez Simó G; Simarro Farinos J; Pujol Marco C; Navarro Mira M; Alegre de Miquel V; Ballester Sánchez R; Sabater Marco V; Llavador Ros M; Palanca Suela S; Botella Estrada R
Br J Dermatol; 2018 Aug; 179(2):394-404. PubMed ID: 29278418
[TBL] [Abstract][Full Text] [Related]
20. Hypermethylation and post-transcriptional regulation of DNA methyltransferases in the ovarian carcinomas of the laying hen.
Lee JY; Jeong W; Lim W; Lim CH; Bae SM; Kim J; Bazer FW; Song G
PLoS One; 2013; 8(4):e61658. PubMed ID: 23613894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
